or Try an Advanced Search...

    Entospletinib Stocks List

    Symbol Grade Name % Change
    AFMD F Affimed Therapeutics B.V. 2.86
    KRON F Kronos Bio, Inc. -0.98
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Biology Blastoma CD19 Cancer Cancer Therapeutics Chronic Lymphocytic Leukemia Clinical Development Cyclin Dependent Kinase Enzymes Epidermal Growth Factor Receptor Glioblastoma Head And Neck Cancer Hematologic Malignancies Hodgkin Lymphoma Immunotherapies Lymphocytic Leukemia Lymphoma

    Related ETFs - A few ETFs which own one or more of the above listed Entospletinib stocks.

    Symbol Grade Name Weight
    IWC B iShares Microcap ETF 0.01
    AVSC B Avantis U.S. Small Cap Equity ETF 0.0
    VXF B Vanguard Extended Market ETF 0.0
    View all Entospletinib ETFs...
    Compare ETFs
    Compare AVSC to VXF Compare IWC to AVSC Compare IWC to VXF

        Entospletinib Stocks Recent News

        Date Stock Title
        May 14 AFMD Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 Congress
        May 14 AFMD Immatics (IMTX) Reports Q1 Loss, Tops Revenue Estimates
        May 10 KRON Kronos Bio GAAP EPS of -$0.50 misses by $0.08, revenue of $2.52M
        May 9 KRON Kronos Bio, Inc. (KRON) Reports Q1 Loss, Tops Revenue Estimates
        May 9 KRON Kronos Bio Reports First-Quarter 2024 Financial Results
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Solid Tumors Acute Myeloid Leukemia Biology Blastoma CD19 Cancer Cancer Therapeutics Chronic Lymphocytic Leukemia Clinical Development Cyclin Dependent Kinase Enzymes Epidermal Growth Factor Receptor Glioblastoma Head And Neck Cancer Hematologic Malignancies Hodgkin Lymphoma Immunotherapies Lymphocytic Leukemia Lymphoma
        Entospletinib

        Entospletinib is an experimental drug for the treatment of various types of cancer under development by Gilead Sciences. It is an inhibitor of spleen tyrosine kinase (Syk). It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).

        More about Entospletinib
        Browse All Tags